+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Phacoemulsification Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 119 Pages
  • November 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294578
The phacoemulsification devices market size is expected to grow from USD 3.44 billion in 2026 to USD 3.64 billion in 2027 and is forecast to reach USD 4.82 billion by 2032 at 5.79% CAGR over 2027-2032. This report is Segmented by Product Type (Consumables and Systems), Technology (Ultrasound Phacoemulsification and More), End User (Hospitals, Ophthalmic Clinics, and More), Application (Cataract Surgery, Refractive Lens Exchange, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Phacoemulsification Devices Market Trends and Insights

Rising Cataract Surgery Volume from Population Aging

The phacoemulsification devices market benefits from the sustained growth of the older population and the resulting need for cataract treatment. Global cataract prevalence among people aged 60 years and older reached 7,748.5 cases per 100,000 people in 2021. Population growth accounted for 87.4% of the increase in the cataract burden between 1990 and 2021. Japanese claims data showed that cataract surgery volumes rose above 2018 levels across age groups between fiscal 2018 and fiscal 2022, even where the population aged 65 to 74 declined. This pattern supports demand for systems and disposable procedure supplies in mature markets, while lower-resource settings require affordable systems and reliable supply chains. The phacoemulsification devices market therefore depends on both procedure access and providers’ ability to add surgical capacity.

Installed-Base-Linked Recurring Consumables Demand

A console installation creates continued demand for compatible cassettes, tubing, tips, sleeves, and procedure packs. These products are designed for the platform’s fluidics and handpiece configuration, which limits direct substitution in routine use. Consumables held 52.45% of revenue in 2026, reflecting this recurring procedural requirement. Alcon reported USD 769 million in surgical consumables revenue in the first quarter of 2026, with growth of 8% from the prior year. The phacoemulsification devices market gains resilience because each active installed system requires a fresh set of supplies for procedures. Manufacturers also have an incentive to support console upgrades because an upgrade can extend their compatible consumable relationship with the facility.

Premium Console and Service-Contract Costs

Premium platforms require a sizable capital commitment, especially when they include active fluidics, laser compatibility, and digital surgical features. Their ongoing cost also includes authorized maintenance, proprietary components, and handpiece service. A 2026 review reported that femtosecond laser-assisted cataract surgery can face cost-effectiveness challenges in public health systems, even though it can offer advantages in complex cases. Independent ambulatory surgery centers must weigh these costs against the clinical value of upgrades in standard cases. The phacoemulsification devices market has responded with shared-access arrangements and systems designed for a smaller footprint. Higher procedure throughput may improve the economics of a console, but it does not remove the initial capital hurdle for every provider.

Other drivers and restraints analyzed in the detailed report include:

  1. Migration of Routine Cataract Cases to Ambulatory and Office-Based Settings
  2. Lower-Energy Fluidics and Intelligent Phaco Platform Innovation
  3. Shortage of Trained Ophthalmic Surgeons and Biomedical Support

Segment Analysis

Consumables held 52.45% of revenue in 2026, giving them the largest phacoemulsification devices market share within the product category. Each cataract procedure requires products such as a cassette, tubing, irrigation and aspiration components, tips, sleeves, and procedure packs. Platform-specific design connects these purchases to the installed console base and gives suppliers recurring sales after an initial equipment placement. This model helps facilities standardize workflows and maintain familiar settings for surgical teams. It also encourages manufacturers to protect compatibility, supply reliability, and clinical support across their existing base. The phacoemulsification devices industry relies on this recurring demand because it stabilizes revenue between large equipment purchases.

Manufacturers are also updating disposable designs to reduce waste and improve handling. Johnson & Johnson Vision introduced SmartLOAD Delivery Technology in October 2026, pairing a reusable titanium inserter with a preloaded cartridge. The company stated that clinical evaluations showed 93% of surgeons expected fewer loading errors and 55-75% less packaging waste than competing preloaded systems. European procurement teams are also operating under the EU Medical Device Regulation, which raises the value of documented product quality and compliance. These factors make waste reduction, usability, and sterility relevant product requirements. The phacoemulsification devices market may see purchasing decisions increasingly consider the full procedure pack rather than only the unit cost of individual consumables.

Ultrasound phacoemulsification held 82.43% of revenue in 2026 and remains the leading technology in the phacoemulsification devices market. It has an established clinical history, broad service support, and a lower cost base than laser-assisted alternatives. Comparative research published in 2025 found differences in ultrasound time and fluidics performance among leading phaco systems used in routine cataract procedures. This means ultrasound remains a category with meaningful platform differentiation rather than a uniform equipment segment. In the United States, the Food and Drug Administration’s 510(k) pathway is a key clearance route for systems and modifications, while IEC 60601-2-5 addresses ultrasound safety requirements for equipment. These compliance factors can extend product development and commercialization timelines.

Femtosecond laser-assisted phacoemulsification is forecast to grow at an 8.54% CAGR through 2032, the highest rate in the technology segment. A 2026 network meta-analysis found that the five assessed laser platforms reduced cumulative dissipated energy compared with conventional phacoemulsification. The clinical case for this approach is stronger for hard nuclei, white cataracts, shallow anterior chambers, and posterior polar cataracts. Cost and access remain barriers to wider use in standard cases. The Federal Trade Commission’s intervention against Alcon’s proposed LENSAR acquisition preserved separate competition between major laser-assisted cataract surgery suppliers. The phacoemulsification devices industry therefore continues to use clinical differentiation and product integration as major competitive tools.

Complete Report Scope:

  • By Product Type
    • Phacoemulsification Consumables
      • Phaco Packs and Cassettes
      • Irrigation and Aspiration Tubing
      • Phaco Tips, Sleeves, and Handpiece Accessories
      • Foot Pedals and Other Procedure Accessories
    • Phacoemulsification Systems
      • Standalone Phacoemulsification Systems
      • Combined Phaco-Vitrectomy Systems
      • Portable Phacoemulsification Systems
  • By Technology
    • Ultrasound Phacoemulsification
    • Femtosecond Laser-Assisted Phacoemulsification
    • Other Phacoemulsification Technologies
  • By End User
    • Hospitals
    • Ophthalmic Clinics
    • Ambulatory Surgery Centers
    • Other End Users
  • By Application
    • Cataract Surgery
    • Refractive Lens Exchange
    • Secondary Lens Removal Procedures
    • Combined Phacovitrectomy Procedures
  • Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 41.32% of revenue in 2026, the largest regional share. The region has established reimbursement pathways, a large installed base of premium systems, and extensive ambulatory surgery center capacity. The United States remains important for premium cataract workflows and physician-owned outpatient centers. Medicare policy has a direct effect on facility economics and equipment replacement decisions. MedPAC continues to track ambulatory surgical center services, reflecting their place within the Medicare program. Alcon launched UNITY Cataract System in Canada during 2026 following Health Canada approval for UNITY VCS in 2025. These launches show that the region remains a key location for adoption of high-performance surgical platforms.

Asia-Pacific is forecast to grow at a 6.43% CAGR through 2032, making it the fastest-growing regional segment. The region carries a high cataract burden, particularly in South Asia, where age-standardized prevalence is high among adults aged 60 years and older. Growth depends on wider access to trained surgeons, operating rooms, maintenance services, and consistent consumable supply. Government-supported eye care capacity can create demand for mid-tier systems that are suitable for high-volume settings. Workforce shortages and rural access gaps remain material constraints across several countries. Japan adds a mature demand profile, where claims data show sustained cataract surgery activity despite demographic changes.

Europe has strong public-payer coverage and a dense network of ophthalmic hospitals and clinics, which supports demand for advanced systems and consumables. EU Medical Device Regulation requirements can raise documentation and compliance demands for smaller suppliers. BVI Medical received a CE Mark under the regulation for Virtuoso during 2026. Zeiss also launched the DORC EVA NEXUS cataract configuration in select European markets in 2026. Middle Eastern and African settings have large unmet needs, where the World Health Organization is supporting regional eye hospital networks to strengthen specialized capacity. South American demand is shaped by private ophthalmic clinics and the gradual spread of advanced cataract procedures in major urban centers. These mixed regions require different pricing, service, and training approaches rather than a single commercial model.



List of Companies Covered in this Report:

  1. Alcon
  2. Appasamy Associates
  3. Bausch + Lomb Corporation
  4. Beaver-Visitec International, Inc.
  5. BVI Medical
  6. Carl Zeiss
  7. D.O.R.C. Dutch Ophthalmic Research Center
  8. GEUDER
  9. HOYA
  10. Johnson & Johnson
  11. LIGHTMED Corporation
  12. LUMed GmbH
  13. Medical Technical Products
  14. Nidek
  15. Optikon 2000 S.p.A.
  16. Oertli Instrumente AG
  17. Rayner
  18. SIFI S.p.A.
  19. Ziemer Group

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope Of The Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Cataract Surgery Volume From Population Aging
4.2.2 Installed-Base-Linked Recurring Consumables Demand
4.2.3 Migration of Routine Cases to Ambulatory and Office-Based Settings
4.2.4 Lower-Energy Fluidics and Intelligent Phaco Platform Innovation
4.2.5 Government and Philanthropic Cataract-Access Programs in Underserved Markets
4.2.6 Platform Compatibility Lock-In and Replacement-Cycle Upgrades
4.3 Market Restraints
4.3.1 Premium Console and Service-Contract Costs
4.3.2 Shortage of Trained Ophthalmic Surgeons and Biomedical Support
4.3.3 Uneven Reimbursement and Surgical Access in Lower-Income Markets
4.3.4 Sterility, Waste, and Feedstock Volatility for Single-Use Consumables
4.4 Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat Of New Entrants
4.7.2 Bargaining Power Of Buyers
4.7.3 Bargaining Power Of Suppliers
4.7.4 Threat Of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Product Type
5.1.1 Phacoemulsification Consumables
5.1.1.1 Phaco Packs and Cassettes
5.1.1.2 Irrigation and Aspiration Tubing
5.1.1.3 Phaco Tips, Sleeves, and Handpiece Accessories
5.1.1.4 Foot Pedals and Other Procedure Accessories
5.1.2 Phacoemulsification Systems
5.1.2.1 Standalone Phacoemulsification Systems
5.1.2.2 Combined Phaco-Vitrectomy Systems
5.1.2.3 Portable Phacoemulsification Systems
5.2 By Technology
5.2.1 Ultrasound Phacoemulsification
5.2.2 Femtosecond Laser-Assisted Phacoemulsification
5.2.3 Other Phacoemulsification Technologies
5.3 By End User
5.3.1 Hospitals
5.3.2 Ophthalmic Clinics
5.3.3 Ambulatory Surgery Centers
5.3.4 Other End Users
5.4 By Application
5.4.1 Cataract Surgery
5.4.2 Refractive Lens Exchange
5.4.3 Secondary Lens Removal Procedures
5.4.4 Combined Phacovitrectomy Procedures
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles {(Includes Global Level Overview, Market Level Overview, Core Segments, Financials As Available, Strategic Information, Market Rank/Share For Key Companies, Products & Services, And Recent Developments)}
6.3.1 Alcon Inc.
6.3.2 Appasamy Associates
6.3.3 Bausch + Lomb Corporation
6.3.4 Beaver-Visitec International, Inc.
6.3.5 BVI Medical
6.3.6 Carl Zeiss Meditec AG
6.3.7 D.O.R.C. Dutch Ophthalmic Research Center
6.3.8 Geuder AG
6.3.9 HOYA Corporation
6.3.10 Johnson & Johnson Vision
6.3.11 LIGHTMED Corporation
6.3.12 LUMed GmbH
6.3.13 Medical Technical Products
6.3.14 NIDEK Co., Ltd.
6.3.15 Optikon 2000 S.p.A.
6.3.16 Oertli Instrumente AG
6.3.17 Rayner
6.3.18 SIFI S.p.A.
6.3.19 Ziemer Ophthalmic Systems AG
7 Market Opportunities & Future Outlook
7.1 White-Space & Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Alcon Inc.
  • Appasamy Associates
  • Bausch + Lomb Corporation
  • Beaver-Visitec International, Inc.
  • BVI Medical
  • Carl Zeiss Meditec AG
  • D.O.R.C. Dutch Ophthalmic Research Center
  • Geuder AG
  • HOYA Corporation
  • Johnson & Johnson Vision
  • LIGHTMED Corporation
  • LUMed GmbH
  • Medical Technical Products
  • NIDEK Co., Ltd.
  • Optikon 2000 S.p.A.
  • Oertli Instrumente AG
  • Rayner
  • SIFI S.p.A.
  • Ziemer Ophthalmic Systems AG